Results 191 to 200 of about 8,771 (219)

Upadacitinib

Reactions Weekly
  +35 more sources

Upadacitinib

Reactions Weekly, 2023
  +12 more sources

Upadacitinib: First Approval

Drugs, 2019
Upadacitinib (Rinvoq™), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of ...
Sean, Duggan, Susan J, Keam
openaire   +2 more sources

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Lancet, The, 2021
E Guttman-Yassky, Ka Papp, Andrew Blauvelt   +2 more
exaly  

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Lancet, The, 2022
Silvio Danese, Xavier Hébuterne, Hiroshi Nakase   +2 more
exaly